Favorable Outcomes of Preterm Infants with Parenteral Nutrition-associated Liver Disease Treated with Intravenous Fish Oil-based Lipid Emulsion

Michael Sorrell, Alvaro Moreira, Kay Green, Rachel Jacob, Robin Tragus, Laura Keller, Amy Quinn, Donald McCurnin, Alice Gong, Abeer El Sakka, Naveen Mittal, Cynthia Blanco

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: The aim of the study was to determine the acute and long-term outcomes of preterm infants treated with an intravenous fish oil-based lipid emulsion (FishLE) for parenteral nutrition-associated liver disease (PNALD). Methods: Preterm infants 14 days to 24 months of age with anatomic short gut or severe intestinal dysmotility, serum direct bilirubin ≥4 mg/dL, and requiring >60% calories from parenteral nutrition were eligible. Enrolled infants received 1 g·kg -1 ·day -1 of FishLE until resolution of direct hyperbilirubinemia or return of enteral nutrition. Acute clinical effects and biochemical markers of liver function were monitored. Growth and developmental scores at 6 and 12 months postmenstrual age (PMA) were assessed and compared with controls matched by gestational age (GA). Results: Thirteen patients with mean GA of 28±4 weeks were treated and compared with 119 GA-matched controls. Their mean direct bilirubin was 9.8±6.4 mg/dL at enrollment. All infants had resolution of cholestasis after study completion. There were no acute adverse events, deaths, or liver/intestinal transplants. Weight and head circumference were similar between FishLE-treated patients and controls at 6- and 12-month PMA. Cognitive and motor scores were decreased at 6 and 12 months PMA in FishLE-treated infants. Logistic regression analysis showed that prolonged hospitalization was detrimental to cognitive and motor development, whereas treatment was not. Conclusions: The use of intravenous FishLEs in premature infants appears to be safe and reverses PNALD despite significant liver disease and intestinal failure. This therapy should be used in preterm infants with PNALD and followed long term to evaluate development.

Original languageEnglish (US)
Pages (from-to)783-788
Number of pages6
JournalJournal of pediatric gastroenterology and nutrition
Volume64
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Fish Oils
Parenteral Nutrition
Emulsions
Premature Infants
Liver Diseases
Gestational Age
Lipids
Bilirubin
Biomarkers
Hyperbilirubinemia
Liver
Cholestasis
Enteral Nutrition
Hospitalization
Logistic Models
Head
Regression Analysis
Transplants
Weights and Measures
Therapeutics

Keywords

  • fish oil
  • infants
  • outcomes
  • parenteral nutrition-associated liver disease
  • prematurity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

Favorable Outcomes of Preterm Infants with Parenteral Nutrition-associated Liver Disease Treated with Intravenous Fish Oil-based Lipid Emulsion. / Sorrell, Michael; Moreira, Alvaro; Green, Kay; Jacob, Rachel; Tragus, Robin; Keller, Laura; Quinn, Amy; McCurnin, Donald; Gong, Alice; El Sakka, Abeer; Mittal, Naveen; Blanco, Cynthia.

In: Journal of pediatric gastroenterology and nutrition, Vol. 64, No. 5, 01.05.2017, p. 783-788.

Research output: Contribution to journalArticle

Sorrell, Michael ; Moreira, Alvaro ; Green, Kay ; Jacob, Rachel ; Tragus, Robin ; Keller, Laura ; Quinn, Amy ; McCurnin, Donald ; Gong, Alice ; El Sakka, Abeer ; Mittal, Naveen ; Blanco, Cynthia. / Favorable Outcomes of Preterm Infants with Parenteral Nutrition-associated Liver Disease Treated with Intravenous Fish Oil-based Lipid Emulsion. In: Journal of pediatric gastroenterology and nutrition. 2017 ; Vol. 64, No. 5. pp. 783-788.
@article{d186a3f663a643949ea47102a532cbfd,
title = "Favorable Outcomes of Preterm Infants with Parenteral Nutrition-associated Liver Disease Treated with Intravenous Fish Oil-based Lipid Emulsion",
abstract = "Objectives: The aim of the study was to determine the acute and long-term outcomes of preterm infants treated with an intravenous fish oil-based lipid emulsion (FishLE) for parenteral nutrition-associated liver disease (PNALD). Methods: Preterm infants 14 days to 24 months of age with anatomic short gut or severe intestinal dysmotility, serum direct bilirubin ≥4 mg/dL, and requiring >60{\%} calories from parenteral nutrition were eligible. Enrolled infants received 1 g·kg -1 ·day -1 of FishLE until resolution of direct hyperbilirubinemia or return of enteral nutrition. Acute clinical effects and biochemical markers of liver function were monitored. Growth and developmental scores at 6 and 12 months postmenstrual age (PMA) were assessed and compared with controls matched by gestational age (GA). Results: Thirteen patients with mean GA of 28±4 weeks were treated and compared with 119 GA-matched controls. Their mean direct bilirubin was 9.8±6.4 mg/dL at enrollment. All infants had resolution of cholestasis after study completion. There were no acute adverse events, deaths, or liver/intestinal transplants. Weight and head circumference were similar between FishLE-treated patients and controls at 6- and 12-month PMA. Cognitive and motor scores were decreased at 6 and 12 months PMA in FishLE-treated infants. Logistic regression analysis showed that prolonged hospitalization was detrimental to cognitive and motor development, whereas treatment was not. Conclusions: The use of intravenous FishLEs in premature infants appears to be safe and reverses PNALD despite significant liver disease and intestinal failure. This therapy should be used in preterm infants with PNALD and followed long term to evaluate development.",
keywords = "fish oil, infants, outcomes, parenteral nutrition-associated liver disease, prematurity",
author = "Michael Sorrell and Alvaro Moreira and Kay Green and Rachel Jacob and Robin Tragus and Laura Keller and Amy Quinn and Donald McCurnin and Alice Gong and {El Sakka}, Abeer and Naveen Mittal and Cynthia Blanco",
year = "2017",
month = "5",
day = "1",
doi = "10.1097/MPG.0000000000001397",
language = "English (US)",
volume = "64",
pages = "783--788",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Favorable Outcomes of Preterm Infants with Parenteral Nutrition-associated Liver Disease Treated with Intravenous Fish Oil-based Lipid Emulsion

AU - Sorrell, Michael

AU - Moreira, Alvaro

AU - Green, Kay

AU - Jacob, Rachel

AU - Tragus, Robin

AU - Keller, Laura

AU - Quinn, Amy

AU - McCurnin, Donald

AU - Gong, Alice

AU - El Sakka, Abeer

AU - Mittal, Naveen

AU - Blanco, Cynthia

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objectives: The aim of the study was to determine the acute and long-term outcomes of preterm infants treated with an intravenous fish oil-based lipid emulsion (FishLE) for parenteral nutrition-associated liver disease (PNALD). Methods: Preterm infants 14 days to 24 months of age with anatomic short gut or severe intestinal dysmotility, serum direct bilirubin ≥4 mg/dL, and requiring >60% calories from parenteral nutrition were eligible. Enrolled infants received 1 g·kg -1 ·day -1 of FishLE until resolution of direct hyperbilirubinemia or return of enteral nutrition. Acute clinical effects and biochemical markers of liver function were monitored. Growth and developmental scores at 6 and 12 months postmenstrual age (PMA) were assessed and compared with controls matched by gestational age (GA). Results: Thirteen patients with mean GA of 28±4 weeks were treated and compared with 119 GA-matched controls. Their mean direct bilirubin was 9.8±6.4 mg/dL at enrollment. All infants had resolution of cholestasis after study completion. There were no acute adverse events, deaths, or liver/intestinal transplants. Weight and head circumference were similar between FishLE-treated patients and controls at 6- and 12-month PMA. Cognitive and motor scores were decreased at 6 and 12 months PMA in FishLE-treated infants. Logistic regression analysis showed that prolonged hospitalization was detrimental to cognitive and motor development, whereas treatment was not. Conclusions: The use of intravenous FishLEs in premature infants appears to be safe and reverses PNALD despite significant liver disease and intestinal failure. This therapy should be used in preterm infants with PNALD and followed long term to evaluate development.

AB - Objectives: The aim of the study was to determine the acute and long-term outcomes of preterm infants treated with an intravenous fish oil-based lipid emulsion (FishLE) for parenteral nutrition-associated liver disease (PNALD). Methods: Preterm infants 14 days to 24 months of age with anatomic short gut or severe intestinal dysmotility, serum direct bilirubin ≥4 mg/dL, and requiring >60% calories from parenteral nutrition were eligible. Enrolled infants received 1 g·kg -1 ·day -1 of FishLE until resolution of direct hyperbilirubinemia or return of enteral nutrition. Acute clinical effects and biochemical markers of liver function were monitored. Growth and developmental scores at 6 and 12 months postmenstrual age (PMA) were assessed and compared with controls matched by gestational age (GA). Results: Thirteen patients with mean GA of 28±4 weeks were treated and compared with 119 GA-matched controls. Their mean direct bilirubin was 9.8±6.4 mg/dL at enrollment. All infants had resolution of cholestasis after study completion. There were no acute adverse events, deaths, or liver/intestinal transplants. Weight and head circumference were similar between FishLE-treated patients and controls at 6- and 12-month PMA. Cognitive and motor scores were decreased at 6 and 12 months PMA in FishLE-treated infants. Logistic regression analysis showed that prolonged hospitalization was detrimental to cognitive and motor development, whereas treatment was not. Conclusions: The use of intravenous FishLEs in premature infants appears to be safe and reverses PNALD despite significant liver disease and intestinal failure. This therapy should be used in preterm infants with PNALD and followed long term to evaluate development.

KW - fish oil

KW - infants

KW - outcomes

KW - parenteral nutrition-associated liver disease

KW - prematurity

UR - http://www.scopus.com/inward/record.url?scp=84984713107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984713107&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000001397

DO - 10.1097/MPG.0000000000001397

M3 - Article

C2 - 28437326

AN - SCOPUS:84984713107

VL - 64

SP - 783

EP - 788

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 5

ER -